Yield10 Bioscience Announces Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall St set for lower open as Alphabet results reignite AI spending fears
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
- ServiceNow (NOW) Misses Q3 EPS by 2c, Beats on Revenue; Offers Q4 Revenue Guidance
- Oracle sets $225 billion revenue target for FY30 at investor day
- Rivian shares slip ahead of Thursday earnings release
- Marvell in advanced talks to acquire Lumentum, Bloomberg reports
- Moderna stock rises on latest cancer vaccine data publication
Yield10 Bioscience, Inc. (YTEN) Reports Q2 Loss of $0.24
August 9, 2018 4:06 PM EDTYield10 Bioscience, Inc. (NASDAQ: YTEN) reported Q2 EPS of ($0.24).
A key highlight of the second quarter is the completion of planting for our 2018 field tests of C3003, said Oliver P. Peoples, Ph.D., President and Chief Executive Officer of Yield10 Bioscience. The results of these field tests will allow us to set the direction and priorities for the next steps in the evaluation and development of C3003 as a potentially valuable new... More



